Cargando…

Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD

INTRODUCTION/OBJECTIVE: ADHD is, for many people, a lifelong disease that requires chronic medication use. Stimulant therapy is often recommended as first-line treatment for ADHD. Adherence to stimulant treatment among patients diagnosed with ADHD is poor. Major regulatory agencies have recommended...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardo, Antonio, King, Thomas R, Rafla, Eman, Kando, Judith C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275141/
https://www.ncbi.nlm.nih.gov/pubmed/34262263
http://dx.doi.org/10.2147/DDDT.S309378
_version_ 1783721671260110848
author Pardo, Antonio
King, Thomas R
Rafla, Eman
Kando, Judith C
author_facet Pardo, Antonio
King, Thomas R
Rafla, Eman
Kando, Judith C
author_sort Pardo, Antonio
collection PubMed
description INTRODUCTION/OBJECTIVE: ADHD is, for many people, a lifelong disease that requires chronic medication use. Stimulant therapy is often recommended as first-line treatment for ADHD. Adherence to stimulant treatment among patients diagnosed with ADHD is poor. Major regulatory agencies have recommended measurement of palatability for new tablet formulations. A new amphetamine extended-release tablet (AMPH ER TAB) for the treatment of attention-deficit/hyperactivity disorder (ADHD) was developed. The AMPH ER TAB has a bubblegum flavor and can be chewed or swallowed whole. In 2016, the FDA developed a draft guidance document on the topic of chewable drug tablet formulation palatability. METHODS: A palatability study of the AMPH ER TAB using the 2016 FDA guidance was conducted. Subjects were asked to assess the taste, aftertaste, and mouthfeel of the tablet formulation using a short questionnaire. Scores from the questionnaire were rated and presented. RESULTS: The substudy assessed 35 subjects with a mean age of 38 (±11) years. Subjects were predominantly male, non-Hispanic, and White. Most subjects rated the oral sensation/mouth feel and taste of the tablet as positive (pleasant to very pleasant) (70.1% and 83.6%, respectively). Additionally, 86.6% of the subjects rated the strength of the taste as neutral (moderate taste) or positive (mild to no taste). Finally, 82.1% of all subjects rated the aftertaste as positive (pleasant to very pleasant) and 92.5% of subjects rated the strength of the aftertaste as neutral or positive (mild to no taste). The trends in evaluation scores for each question were similar regardless of whether the ER chewable tablet was administered under fasted or fed conditions. CONCLUSION: The positive palatability data presented here will be useful for future “real-world” assessments of adherence to treatment with the AMPH ER TAB. Enhanced adherence may bolster the argument that taste, mouthfeel, and aftertaste are critical determinants of treatment adherence.
format Online
Article
Text
id pubmed-8275141
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82751412021-07-13 Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD Pardo, Antonio King, Thomas R Rafla, Eman Kando, Judith C Drug Des Devel Ther Original Research INTRODUCTION/OBJECTIVE: ADHD is, for many people, a lifelong disease that requires chronic medication use. Stimulant therapy is often recommended as first-line treatment for ADHD. Adherence to stimulant treatment among patients diagnosed with ADHD is poor. Major regulatory agencies have recommended measurement of palatability for new tablet formulations. A new amphetamine extended-release tablet (AMPH ER TAB) for the treatment of attention-deficit/hyperactivity disorder (ADHD) was developed. The AMPH ER TAB has a bubblegum flavor and can be chewed or swallowed whole. In 2016, the FDA developed a draft guidance document on the topic of chewable drug tablet formulation palatability. METHODS: A palatability study of the AMPH ER TAB using the 2016 FDA guidance was conducted. Subjects were asked to assess the taste, aftertaste, and mouthfeel of the tablet formulation using a short questionnaire. Scores from the questionnaire were rated and presented. RESULTS: The substudy assessed 35 subjects with a mean age of 38 (±11) years. Subjects were predominantly male, non-Hispanic, and White. Most subjects rated the oral sensation/mouth feel and taste of the tablet as positive (pleasant to very pleasant) (70.1% and 83.6%, respectively). Additionally, 86.6% of the subjects rated the strength of the taste as neutral (moderate taste) or positive (mild to no taste). Finally, 82.1% of all subjects rated the aftertaste as positive (pleasant to very pleasant) and 92.5% of subjects rated the strength of the aftertaste as neutral or positive (mild to no taste). The trends in evaluation scores for each question were similar regardless of whether the ER chewable tablet was administered under fasted or fed conditions. CONCLUSION: The positive palatability data presented here will be useful for future “real-world” assessments of adherence to treatment with the AMPH ER TAB. Enhanced adherence may bolster the argument that taste, mouthfeel, and aftertaste are critical determinants of treatment adherence. Dove 2021-07-08 /pmc/articles/PMC8275141/ /pubmed/34262263 http://dx.doi.org/10.2147/DDDT.S309378 Text en © 2021 Pardo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Pardo, Antonio
King, Thomas R
Rafla, Eman
Kando, Judith C
Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
title Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
title_full Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
title_fullStr Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
title_full_unstemmed Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
title_short Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
title_sort assessing palatability of a new amphetamine extended-release tablet formulation for the treatment of adhd
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275141/
https://www.ncbi.nlm.nih.gov/pubmed/34262263
http://dx.doi.org/10.2147/DDDT.S309378
work_keys_str_mv AT pardoantonio assessingpalatabilityofanewamphetamineextendedreleasetabletformulationforthetreatmentofadhd
AT kingthomasr assessingpalatabilityofanewamphetamineextendedreleasetabletformulationforthetreatmentofadhd
AT raflaeman assessingpalatabilityofanewamphetamineextendedreleasetabletformulationforthetreatmentofadhd
AT kandojudithc assessingpalatabilityofanewamphetamineextendedreleasetabletformulationforthetreatmentofadhd